Unlearn.Ai announced it raised $50 Million in an initial filing from an offering of $50 Million

Company

Location

About

Unlearn partners with pharma and biotech companies to design and optimize clinical trials using AI-powered digital twins. By forecasting patients’ clinical outcomes, Unlearn helps sponsors refine trial design, shorten timelines, and increase the chance of detecting treatment effects in less time. With a science-first approach and deep regulatory engagement—including EMA qualification and FDA endorsement—Unlearn is transforming clinical development to be faster, smarter, and more reliable.